CNS Pharmaceuticals, Inc.

NASDAQ: CNSP · Healthcare · Biotechnology

PublicHQ Houston, TX · HarrisCIK 0001729427Reports USD

#1 of 1,422 Healthcare companies by revenue

EA Score

——

FH 22DQ —GM —SS 34

v0.1 · 35/100 weight · pillars only

↑ balance-sheet leverage, market scale · ↓ Piotroski F, return on equity

Methodology →

Revenue TTM

Rev growth YoY (TTM)

needs 8 qtrs

Net income (FY)

-$15.9M

Employees

as of 2026-08-24

Market cap

$8.5M

as of 2026-08-24

Financials — latest annual

SEC EDGAR · USD-normalized

ConceptUSDNativeFY

Net income-$15.9M-$15.9M2025

Operating income-$16.0M-$16.0M2025

Total assets$8.6M$8.6M2025

Liabilities$4.1M$4.1M2025

Equity$4.5M$4.5M2025

Revenue by segment

No segmentation disclosed for this filer. n/a

The read

What is CNS Pharmaceuticals, Inc.’s financial profile?

CNS Pharmaceuticals, Inc. earned -$15.9M in FY2025 net income.

Peers · Healthcare

Skye Bioscience, Inc.——Quince Therapeutics, Inc.——CalciMedica, Inc.——AEON Biopharma, Inc.——AI Maverick Intel, Inc.——Aprea Therapeutics, Inc.——

Neighbors

Harris →

Exxon Mobil Corporation$332.2B77B+Chevron Corporation$184.4B71B ConocoPhillips$51.8B76B+Quanta Services, Inc.$28.5B68B Waste Management, Inc.$25.2B82B+Phillips 66$132.4B73B

Key facts

CEORami Levin

SectorHealthcare

IndustryBiotechnology

HeadquartersHouston, TX

ExchangeNASDAQ: CNSP

Employees8

IPO date2019-11-08

Latest filings

DEF 14A2026-08-21 10-Q2026-08-12 8-K2026-07-02 10-Q2026-05-14 8-K2026-05-04 10-K2026-03-31 8-K2026-03-11 8-K2026-03-02

Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.